Elevated homocysteine (Hcy) concentrations are associated with increased risk of several chronic diseases. Hcy can be removed by methylating it to form methionine via either the betaine homocysteine S-methyltransferase (BHMT) or the methionine synthase (MS) pathway. BHMT uses betaine as the methyl donor, whereas MS uses 5-methyltetrahydrofolate. We previously found that mice with the gene encoding Bhmt deleted (Bhmt 2/2 ) had altered Hcy metabolites in tissues. This study aimed to determine whether folate supplementation of Bhmt 2/2 mice reverses, and folate deficiency exacerbates, these metabolic changes. Bhmt 2/2 mice and their littermates (Bhmt +/+ mice) were fed a folate-deficient (FD; 0 mg/kg diet), a folate control (FC; 2 mg/kg diet), or a folate-supplemented (FS; 20 mg/kg diet) diet for 4 wk. Bhmt 2/2 mice had higher plasma Hcy and hepatic S-adenosylhomocysteine (AdoHcy) concentrations and had lower hepatic Sadenosylmethionine (AdoMet) concentrations compared with Bhmt +/+ mice for all diets. Although the FD diet increased plasma Hcy (P < 0.05) and hepatic AdoHcy (P < 0.001) concentrations in Bhmt +/+ mice compared with FC and FS mice, the FD diet had no effect on the metabolites measured in Bhmt 2/2 mice. The FS diet did not ameliorate elevated plasma Hcy and elevated hepatic AdoHcy concentrations but did increase hepatic AdoMet concentrations in Bhmt 2/2 mice (P < 0.001) compared with FD and FC mice. We conclude that the BHMT pathway is a major route for the elimination of Hcy in mice and that the MS pathway has little excess capacity to methylate the Hcy that accumulates when the BHMT pathway is blocked. J. Nutr.
Introduction
Homocysteine (Hcy) 9 is an amino acid that is not used for protein synthesis. Plasma concentrations of Hcy are positively correlated with increased risk of cardiovascular disease, birth defects, Alzheimer disease, bone weakness, and renal dysfunction (1, 2) . Plasma Hcy concentrations of 5 to 15 mmol/L are considered to be normal in humans, whereas individuals with concentrations of 15 to 100 mmol/L are moderately hyperhomocysteinemic and those with concentrations >100 mmol/L are considered to be severely hyperhomocysteinemic (1, 2) . Normal plasma Hcy concentrations are maintained by converting Hcy to cysteine by action of the enzyme cystathionine b synthase (CBS; EC 4.2.1.22) (Supplemental Fig. 1 ) or by methylating Hcy to form methionine in reactions that can be accomplished by 1 of the 3 separate enzymatic pathways: methionine synthase (MS; EC 2.1.1.13) methylates Hcy by using 5-methyltetrahydrofolate as the methyl donor and vitamin B-12 as a cofactor; betaine homocysteine S-methyltransferase (BHMT; EC 2.1.1.5) methylates Hcy by using betaine as the methyl donor; and BHMT2 (EC 2.1.1.5) methylates Hcy by using S-methylmethionine as the methyl donor. The methionine formed from Hcy serves as the precursor of S-adenosylmethionine (AdoMet), the principal biological methyl donor for numerous methylations, including the methylation of DNA, histones, and phospholipids. When it donates its methyl group, AdoMet is converted to S-adenosylhomocysteine (AdoHcy), and AdoHcy can be recycled to Hcy. Perturbations of these pathways, either by genetic or nongenetic factors (such as diet and drugs), may result in increased Hcy concentrations.
Our laboratory previously reported that mice with the Bhmt gene deleted (Bhmt 2/2 mice) had absent BHMT activity and increased concentrations of Hcy in the liver (by 6-fold; P < 0.01) and in plasma (by 8-fold; P < 0.001) compared with their littermate controls (3). In addition, Bhmt deletion resulted in decreased concentrations of AdoMet (by 40%; P < 0.01) and increased concentrations of AdoHcy (by 3-fold; P < 0.01) in liver (3) . These data suggest that the methyl-folate-mediated methylation of homocysteine cannot maintain normal Hcy concentrations in the absence of Bhmt.
We hypothesized that Bhmt 2/2 mice would be dependent on the folate pathway for remethylation of Hcy, and that they would have higher Hcy concentrations when made folate deficient. Conversely, if MS activity is normally limited by the availability of folate, supplementation with folate would lower Hcy concentrations in Bhmt 2/2 mice.
Materials and Methods
Animals and diets. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill. Bhmt 2/2 mice were generated as described previously (3) . Heterozygous breeding pairs were used to generate Bhmt 2/2 mice and their wild-type littermates (Bhmt +/+ mice) for all experiments. Bhmt genotypes were determined by a PCR-based method as described previously (3) . Mice were housed in a temperaturecontrolled environment at 24°C and exposed to a 12-h light/dark cycle. Six-week-old mice were given free access to water and to the assigned pelleted diets (Dyets) for 4 wk. Mice were assigned to 1 of 3 dietary groups: folate-deficient (FD; AIN-76A diet with 0.0 mg folic acid/kg diet, 1.1 g choline chloride/kg diet, and 1% succinyl sulfathiazole), folate control (FC; AIN-76A diet with 2 mg folic acid/kg diet, 1.1 g choline chloride/kg diet, and 1% succinyl sulfathiazole), or folate-supplemented (FS; AIN-76A diet with 20 mg folic acid/kg diet, 1.1 g choline chloride/ kg diet, and 1% succinyl sulfathiazole) as previously described (4). Succinyl sulfathiazole was added to all diets to kill intestinal bacteria that are able to synthesize folate.
Tissue collection. On the last day of the study, mice were moved to clean cages and feed-deprived for 4 h before tissue collection. Mice were anesthetized by inhalation of isoflurane (Hospira). Body weight was assessed by using a scale. Blood was collected via cardiac puncture. Plasma was separated from blood by centrifugation at 3000 3 g for 5 min at room temperature, frozen immediately in liquid nitrogen, and stored at 280°C until analysis. Livers were harvested, weighed, snapfrozen in liquid nitrogen, and stored at 280°C until used.
Plasma and hepatic metabolites. Plasma total folate concentrations were measured by using a microbiological assay (5). Plasma total Hcy concentrations were measured by using an HPLC method (6). Cysteamine (10 mmol/L) was used as an internal standard to correct for recovery. The concentrations of hepatic AdoMet and AdoHcy were measured by using an HPLC method as previously described (7, 8) .
Statistical analysis. Values are presented as means 6 SEM. Diet 3 genotype effects were analyzed by 2-way ANOVA. Differences between the 3 dietary groups within the same genotype were determined by using 1-way ANOVA and Tukey-KramerÕs honestly significant difference test. Differences between the 2 genotype groups fed the same diet were determined by using StudentÕs t test. JMP version 9.0 (SAS Institute) was used to perform all statistical analysis.
Results
Body and liver weights. Bhmt +/+ and Bhmt 2/2 mice appeared grossly normal on all 3 experimental diets. After 4 wk of consuming the various folate diets, no significant difference was observed in the body weights of mice either by genotype or by diet. The liver weights of both Bhmt +/+ and Bhmt 2/2 mice were not affected by diets but were affected by genotype. Bhmt 2/2 mice had livers 34% and 30% heavier than those of Bhmt +/+ mice fed the FD diet (P < 0.001) and the FS diet, respectively (P < 0.05) ( Table 1 ). The heavier livers observed in the Bhmt 2/2 mice were consistent with our previous findings (3).
Plasma folate. To confirm that the mice were fed the experimental diets, we measured plasma total folate concentrations. Bhmt +/+ and Bhmt 2/2 mice fed the FS diet had increased plasma folate concentrations that were 40% (P < 0.001) and 60% (P < 0.001) greater, respectively, compared with those fed the FC diet (Fig. 1) . Bhmt +/+ and Bhmt 2/2 mice fed the FD diet had plasma folate concentrations that were 84% (P < 0.001) and 95% (P < 0.001) less, respectively, compared with those fed the FC diet. Bhmt 2/2 mice fed the FD diet had lower plasma folate concentrations than did Bhmt +/+ mice fed the same diet (P < 0.05). There was no interaction between diet and genotype for plasma folate concentration.
Plasma homocysteine and cysteine. Mean plasma Hcy concentration in the Bhmt +/+ mice fed the FC diet was 4.61 6 0.36 mmol/L, which is similar to published values (9) (Fig. 2) . Bhmt 2/2 mice fed the FC diet had 8.4-fold greater plasma Hcy concentrations than did Bhmt +/+ mice fed the same diet (P < 0.001), which is consistent with our previous findings (3 mice compared with mice fed the FC diet. With this deficient diet, Bhmt 2/2 mice had 7.6-fold greater plasma Hcy concentrations than did Bhmt +/+ mice (P < 0.0001). Because homocysteine could also be removed by forming cysteine via the CBS pathway, we measured plasma cysteine. No significant difference was observed in plasma cysteine concentration by diet or by genotype (Supplemental Fig. 2 ). There was no interaction between diet and genotype for plasma Hcy or cysteine concentration.
Hepatic AdoMet and AdoHcy. Hepatic AdoHcy concentrations in mice were not affected by the different folate diets but were affected by genotype (Fig. 3A) . Bhmt 2/2 mice fed the FC diet had 2.7-fold greater hepatic AdoHcy concentrations than did Bhmt +/+ mice fed the same diet (P < 0.001), which is consistent with our previous findings (3). Four weeks of consuming the FS diet or the FD diet did not change hepatic AdoHcy concentrations in either Bhmt +/+ or Bhmt 2/2 mice compared with those fed the FC diet. Bhmt 2/2 mice had 2-fold (P < 0.0001) and 1.6-fold (P < 0.0001) greater hepatic AdoHcy concentrations than did Bhmt +/+ mice when fed the FS diet or the FD diet, respectively. Bhmt 2/2 mice fed the FC diet had hepatic AdoMet concentrations that were 54% less than those of Bhmt +/+ mice fed the same diet (P < 0.01), which is consistent with our previous findings (3) (Fig. 3B) . Four weeks of consuming the FS diet had no effect on hepatic AdoMet concentrations in Bhmt +/+ mice compared with those fed the FC diet but increased hepatic AdoMet concentrations in Bhmt 2/2 mice by 30% (P < 0.001). With this supplemented diet, Bhmt 2/2 mice had hepatic AdoMet concentrations that were 36% less than those of Bhmt +/+ mice (P < 0.0001). Four weeks of consuming the FD diet reduced hepatic AdoMet concentrations in Bhmt +/+ mice by 37% (P < 0.05) compared with those fed the FC diet but had no effect on hepatic AdoMet concentrations in Bhmt 2/2 mice. With this deficient diet, Bhmt 2/2 mice had hepatic AdoMet concentrations that were 43% less than those of Bhmt +/+ mice (P < 0.01).
Discussion
Normal plasma Hcy concentrations are maintained by the CBS, MS, or BHMT pathways (Supplemental Fig. 1) . Perturbations of the CBS and MS pathways, either by single nucleotide polymorphisms in the genes or by deficiencies in nutrients involved, result in hyperhomocysteinemia in both humans and rodents (10, 11) . On the other hand, limited information is available on the BHMT pathway. It has been assumed that the CBS and the MS pathways have adequate capacity to handle any Hcy load and that the BHMT pathway provides excess capacity. We, and others, found that the role of BHMT in Hcy metabolism is important because Bhmt 2/2 mice had a substantial increase in plasma and hepatic Hcy concentrations (3, 12) . In addition, Bhmt 2/2 mice had a significant increase in hepatic AdoHcy and a decrease in hepatic AdoMet concentrations. Because the enzyme MS also methylates Hcy to methionine by using 5-methyltetrahydrofolate as the methyl donor, we asked whether dietary folate supplementation would ameliorate, and folate deficiency would exacerbate, these phenotypes presented in Bhmt 2/2 mice. There is a second pathway capable of remethylating Hcy to methionine by using S-methylmethionine as the methyl donor, catalyzed by the enzyme encoded for by BHMT2, but this enzyme uses S-methylmethionine as a substrate and this compound is not found in the purified diet used in this study. We did not see evidence of BHMT2 activity in this study.
Consistent with our previous findings, Bhmt 2/2 mice had heavier livers and higher plasma Hcy, higher hepatic AdoHcy, and lower hepatic AdoMet concentrations compared with those of Bhmt +/+ mice fed a diet adequate in folate (3) . Although folate deficiency resulted in elevated plasma Hcy and hepatic AdoHcy concentrations in Bhmt +/+ mice, we found that the diminished jn.nutrition.org availability of dietary folate did not further exacerbate the high plasma Hcy, high hepatic AdoHcy, or low hepatic AdoMet concentrations observed in Bhmt 2/2 mice. The lack of effects of folate deficiency on these variables in Bhmt 2/2 mice suggests that MS does not make a substantial contribution toward methylating Hcy in these mice. Increased availability of folate did not ameliorate the high plasma Hcy and the high hepatic AdoHcy concentrations observed in Bhmt 2/2 mice. Once again, these data suggest that the MS pathway is not folate-limited in these mice and that there was not excess capacity in this pathway that could be used to make up for loss of BHMT-mediated methylation of Hcy. However, increased folate intake did increase the hepatic AdoMet concentrations in Bhmt 2/2 mice, but only to concentrations similar to those of Bhmt +/+ mice on an FD diet. This may reflect some increased flux through MS pathway but could also be due to activation of methionine adenosyltransferase by AdoHcy.
Our findings show that BHMT-mediated methylation of Hcy is more important than previously appreciated. In mice, the BHMT pathway appears to be the predominant pathway for removal of Hcy, whereas the MS pathway does not appear to have excess capacity to make up for the loss of this pathway (even when mice are provided with excess folate). Mice and humans differ in the relative importance of several steps in Hcy metabolism: for example, mice use much more cysteine as a precursor for hair formation. Despite these differences, the knockout mouse provides a useful guide as to phenotypes that should be examined in humans. A number of single nucleotide polymorphisms in BHMT exist in humans, and we suggest that those that result in loss of BHMT activity could have a phenotype that includes hyperhomocysteinemia. Our current study in mice suggests that these individuals will not be responsive to folate supplementation.
